Abstract
Type 2 diabetes mellitus is characterized by the early onset of insulin resistance. Reduced, responsiveness to normal circulating levels of insulin leads to hyperinsulinemia. When the pancreas is unable to keep up with increased insulin requirements, hyperglycemia ensues. This can influence the development of diabetes mellitus, obesity, hypertension, and dyslipidemia.1,2,3Commonly referred to as “syndrome X,” these complications are associated with an increased risk of coronary heart disease. A new class of drugs, the glitazones, offers the first therapeutic option specifically targeting insulin resistance. The drugs act on tissues such as liver and skeletal muscle, sensitizing them to insulin action, and thereby increasing glucose uptake and decreasing its hepatic output.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
